Update in the management of ovarian and cervical carcinoma

Clinical and Translational Oncology

Volumn 9, Issue 7, 2007, Pages 443-451

  Poveda, A ^a   Salazar, R ^b   del Campo, J M ^c   Mendiola, C ^d   Cassinello, J ^e   Ojeda, B ^f   Arranz, J A ^g   Oaknin, A ^b   Garcia Foncillas J ^h   Rubio, M J ⁱ   Gonzalez Martin A ^j  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h UNIVERSITY CLINIC OF NAVARRA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

more..

Author keywords

Cervical cancer; Chemotherapy; Ovarian cancer; Update

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CANFOSFAMIDE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPOTHILONE B; ERLOTINIB; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN; TRABECTEDIN; UNINDEXED DRUG; WART VIRUS VACCINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CATHETER COMPLICATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SCREENING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE GENITAL TRACT TUMOR; GYNECOLOGIC SURGERY; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYSTERECTOMY; KIDNEY DISEASE; LOW DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; OVARY CARCINOMA; POSTOPERATIVE CARE; QUALITY OF LIFE; RECURRENCE RISK; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA; CARCINOMA; CONFERENCE PAPER; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; OVARY TUMOR; UTERINE CERVIX TUMOR;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA; CISPLATIN; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; UTERINE CERVICAL NEOPLASMS;

EID: 35748970199     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0083-7     Document Type: Article

References (66)

1. Sugarbaker PH, Mora JT, Carmignani P et al (2005) Update on chemotherapeutic agents utilized for perioperative intraperitoneal CT. Oncologist 10:112-122
2. Markman M (2003) Intraperitoneal antineoplastic drug delivery: Rationale and results. Lancet Oncol 14:277-283
3. Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955
4. Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001-1007
5. Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43
6. Jaaback K, Johnson N (2006) Intraperitoneal CT for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 1:CD005340
7. Gore M, du Bois A, Vergote I (2006) Intraperitoneal CT in ovarian cancer remains experimental. J Clin Oncol 24:4528-4530
8. Pecorelli S (2006) The standard of therapy for advanced ovarian cancer: a global perspective. Educational Session, ASCO annual meeting
9. Thigpen JT, Brady MF, Omura GA et al (1993) Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 71:606-614
10. Eisenhauer EA, Vermorken JB, Van Glabbeke M (1997) Predictors of response to subsequent CT in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Ann Oncol 8:963-968
11. Markman M, Reichman B, Hakes T et al (1991) Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol 9:1801-1805
12. Markman M, Markman J, Webster K et al (2004) Duration of response to second-line, platinum-based CT for ovarian cancer: Implications for patient management and clinical trial design. J Clin Oncol 22:3120-3125
13. Gore ME, Fryatt I, Wiltshaw E, Dawson T (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207-211
14. Spriggs D (2003) Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol 90:S39-S44
15. Armstrong DK (2002) Relapsed ovarian cancer: Challenges and management strategies for a chronic disease. Oncologist. 7:20-28
16. Kavanagh J, Tresukosol D, Edwards C et al (1995) Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 13:1584-1588
17. Spriggs DR (2002) Platinum treatment of presumed platinum resistant ovarian cancer after nonplatinum therapy [abstract]. Proc Am Soc Clin Oncol 21:A877
18. Ten Bokkel Huinink W, Gore M, Carmichael J et al (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193
19. Creemers GJ, Bolis G, Gore M et al (1996) Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 14:3056-3061
20. Bookman MA, Malmstrom H, Bolis G et al (1998) Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior CT that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16:3345-3352
21. McGuire WP, Blessing JA, Bookman MA et al (2000) Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 18:1062-1067
22. Horowitz NS, Hua J, Giba R K et al (2004) The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: An in vitro model. Gynecol Oncol 94:67-73
23. Parmar MK, Ledermann JA, Colombo N et al (2003) Paclitaxel plus platinum-based CT versus conventional platinum-based CT in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099-2106
24. González-Martin AJ, Calvo E, Bover I et al (2005) Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: A GEICO (Grupo Españole de Investigación en Cancer de Ovario) study. Ann Oncol 16:749-755
25. Pfisterer J, Plante M, Vergote I et al (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699-4707
26. Markman M, Rothman R, Hakes T et al (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393
27. Markman M, Hoskins W (1992) Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definition of the treated population. J Clin Oncol 10:513-514
28. Thigpen JT, Vance RB, Khansur T (1993) Second-line CT for recurrent carcinoma of the ovary. Cancer 71:1559-1564
29. (2005) Guidelines by the National Institute of Clinical Excellence (NICE). Available on WWW at http://www.nice.org.uk
30. Chi DS, McCaughty K, Diaz JP (2006) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106:1933-1939
31. Harter P, du Bois A, Hahmann M (2006) Surgery in recurrent ovarian cancer: The Arbeitsgeminschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702-1710
32. Doyle C, Crump M, Pintilie M, Oza AM (2001) Does palliative CT palliate? Evaluation of expectations, outcomes, and costs in women receiving CT for advanced ovarian cancer. J Clin Oncol 19:1266-1274
33. Eisenhauer EA, Vermorken JB, Van Glabbeke M (1997) Predictors of response to subsequent CT in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Ann Oncol 8:963-968
34. Leitao MM, Hummer A, Dizon DS et al (2003) Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol 91:123-129
35. Ten Bokkel, Huinink W, Lase SR, Ross GA (2004) Long-term survival in a phase III, randomized study of topotecan versus paclitaxel in advanced epithelial ovarian cancer. Ann Oncol 15:100-103
36. Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubic in versus topotecan. J Clin Oncol 19:3312-3322
37. Bookman MA (2005) Is there still a role for hormonal therapy? Int J Gynecol Cancer 15:291-297
38. Howley PM (2001) In: Fields BN, Knipe DM, Howley PM (eds) Fields virology, 4th Edn. Lippincott-Raven, Philadelphia, PA, pp 2197-2229
39. Rose PG, Bundy BN, Watkins EB (1999) Concurrent cisplatin-based radiotherapy and CT for locally advanced cervical cancer. N Engl J Med 340:1144-1153
40. Bonomi P, Blessing JA, Stehman FB et al (1985) Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 3:1079-1085
41. Omura GA, Blessing JA, Vaccarello L et al (1997) Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 15:165-171
42. Bloss JD, Blessing JA, Behrens BC et al (2002) Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol 20:1832-1837
43. Rose PG, Blessing JA, Gerhenson D, McGehee R (1999) Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol 17:2676-2680
44. Moore DH, Blessing JA, McQuellon RP et al (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol 22:3113-3119
45. Long H, Bundy BN, Grendys EC et al (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23:4626-4633
46. Ciardiello F, Tortora G (2002) Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Invest Drugs 11:755-768
47. Salomon DS, Brandt R, Ciardiello F, Nornanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232
48. Nicodemus CF, Berek JS (2005) Monoclonal antibody therapy of ovarian cancer. Expert Rev Anticancer Ther 5:87-96
49. Ciardiello F, Bianco R, Damiano V et al (1999) Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Can Res 5:909-916
50. Aghajanian C, Sabbatini P, Derosa F et al (2005) Phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal and fallopian tube cancer. J Clin Oncol 23:5047
51. Loibl R et al. Phase II study of gefitinib plus tamoxifen in patients refractory to platinum/taxane-based therapy (AGO Ovar 2.6)
52. Finkler N, Gordon A, Crozier M et al (2001) Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma [abstract]. Proc Am Soc Clin Oncol 20:A831
53. Clark GM, Pérez-Soler R, Sin L et al (2003) Rash severity is predictive of increased survival with erlotinib HCl [abstract]. Proc Am Soc Clin Oncol 22:A786
54. Shen GH, Ghazizaden M, Kawanami O et al (2000) Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 83:196-203
55. Zebrowski BK, Liu W, Ramirez K et al (1999) Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6:373-378
56. Presta L, Chen H, O'Connor SJ et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599
57. Burger RA, Sill M, Monk BJ et al (2005) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study [abstract]. J Clin Oncol 23:A5009
58. Cannistra SA, Matulonis U, Penson R et al (2006) Bevacizumab in patients with advanced platinum-resistant ovarian cancer [abstract]. J Clin Oncol 24:A5006
59. Dupont J, Rothenberg ML, Spriggs DR et al (2005) Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. J Clin Oncol 23:A3029
60. Yao JC, Phan AT, Chang DZ et al (2006) Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET) [abstract]. J Clin Oncol 24:A4042
61. Cascinu S, Del Ferro E, Ligi M et al (2001) Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Invest 19:8-12
62. Pollak MN, Polychronakos C, Guyda H (1989) Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 9:889-891
63. Sessa C, de Braud F, Perotti A et al (2005) Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23:1867-1874
64. McMeekin DS, Krasner C, Chan S et al (2005) Final results of a phase II study of weekly trabectedin in second/third line ovarian carcinoma. J Clin Oncol 23:A5011
65. Del Campo J, Roszak A, Ciuleanu T et al (2006) Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: preliminary results. J Clin Oncol 23:A5031
66. Poveda A (2005) Ovarian cancer: Are the news good enough? Int J Gynecol Cancer 15[Suppl 3]:298-306